# Risankizumab for Fibrostenotic Crohn's Disease Treatment

> **NCT07177118** · PHASE3 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 260 (estimated)

## Conditions studied

- Crohn Disease
- Crohn Disease and Ulcerative Colitis

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT07177118
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2028-06-20
- **Final completion:** 2028-10-20
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177118, "Risankizumab for Fibrostenotic Crohn's Disease Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07177118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*